## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report engineering a DecR variant (N29Y/C81E/M90Q/M99E) of the Lrp/AsnC-type transcriptional regulator from *Escherichia coli* to create a genetically encoded biosensor for L-cysteine. They claim improved specificity and an 8.71-fold increase in dynamic range relative to the wild-type regulator, and use this biosensor for high-throughput screening of a promoter and RBS library, yielding a strain with 6.29-fold increased L-cysteine production. Molecular dynamics simulations and electrophoretic mobility shift analysis are cited to support enhanced induction activity of the variant, attributed to increased DNA binding in the presence of L-cysteine.
- **Visible evidence base** Abstract text only; no quantitative data, experimental details, or statistical analyses are provided beyond the stated fold changes
- **Missing materials affecting confidence** Full manuscript, all figures and tables, methods descriptions, strain and plasmid details, library construction and screening protocols, MD simulation parameters, EMSA conditions, and raw data for production and dynamic range measurements

## Reviewer
- **Overall assessment** The abstract presents a potentially useful biosensor engineering strategy for L-cysteine production, with clear claims of improved dynamic range and production yield. However, the evidence base is limited to summary statements without experimental detail, statistical validation, or comparative controls. The mechanistic interpretation is plausible but not fully substantiated from the provided material. The work may interest metabolic engineers and synthetic biologists, but the case for broad applicability and mechanistic novelty is not fully established from the abstract alone.
- **Who would be interested in the results, and why** Researchers in metabolic engineering, synthetic biology, and industrial biotechnology would be interested in the biosensor-based screening approach for amino acid production. Those working on transcriptional regulator engineering and high-throughput strain optimization would find the DecR variant and its application relevant to similar pathway optimization challenges.
- **Major strengths** The strategy addresses a real bottleneck in L-cysteine production, namely the lack of high-throughput screening methods. The combination of protein engineering, library screening, and mechanistic analysis via MD and EMSA is a coherent workflow. The reported fold improvements in dynamic range and production are substantial if reproducible.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3  
  - R1-M4
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria**  
  - Originality: The approach is not entirely novel, as biosensor-based screening for amino acid production has been reported for other systems, but the specific application to DecR and L-cysteine may offer incremental novelty.  
  - Scientific importance: The work addresses a practical challenge in microbial production of an industrially relevant amino acid, which is of moderate importance.  
  - Interdisciplinary readership: The topic is relevant to metabolic engineering and synthetic biology, but the abstract does not clearly demonstrate broader appeal beyond these fields.  
  - Technical soundness: The claims cannot be fully assessed from the abstract; key experimental controls and statistical analyses are not described.  
  - Readability for nonspecialists: The abstract is reasonably clear but assumes familiarity with biosensor and pathway engineering concepts.
- **Recommendation posture** Supportive if technical concerns are resolved, but currently not established from the provided evidence.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** The variant-based biosensor shows improved specificity and an 8.71-fold increase in dynamic range.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract states a fold increase in dynamic range but does not define how dynamic range was measured, what baseline was used, or whether the improvement is statistically significant. Specificity is claimed but no data on cross-reactivity with other amino acids or metabolites are presented.  
- **Why it matters** Without a clear definition of dynamic range and specificity metrics, the biosensor performance cannot be compared to existing tools or independently validated. This is central to the claimed utility of the biosensor.  
- **Resolution test** Provide a detailed description of the assay used to measure dynamic range, including the wild-type comparator, replicate numbers, and statistical analysis. Include specificity data against a panel of relevant metabolites.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** High-throughput screening of the promoter and RBS library yielded an optimized strain with a 6.29-fold increase in L-cysteine production.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract does not specify the library size, screening conditions, selection criteria, or the number of variants tested. The production increase is reported as a single fold change without reference to the parental strain, culture conditions, or reproducibility across biological replicates.  
- **Why it matters** The claim of successful optimization depends on the robustness of the screening process and the reliability of the production measurement. Without these details, the result cannot be reproduced or assessed for practical significance.  
- **Resolution test** Describe the library construction and screening workflow, including library diversity, screening thresholds, and validation of the final strain. Report production data with standard deviations and statistical tests comparing the optimized strain to a defined control.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Mechanistic support  
- **Claim pointer** MD simulations and EMSA showed that the N29Y/C81E/M90Q/M99E variant had enhanced induction activity, possibly due to increased DNA binding in the presence of L-cysteine.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract provides no details on the MD simulation setup, force fields, simulation length, or how binding was quantified. For EMSA, no data on protein concentrations, DNA probe sequences, or binding affinities are given. The causal link between increased DNA binding and enhanced transcriptional activation is inferred but not directly demonstrated.  
- **Why it matters** The mechanistic explanation is a key part of the claimed advance, as it rationalizes the engineered mutations. Without adequate methodological detail and quantitative binding data, the mechanism remains speculative.  
- **Resolution test** Provide MD simulation parameters and analysis of binding free energies or interaction contacts. Include EMSA data with dose-response curves and calculated dissociation constants for the variant versus wild-type in the presence and absence of L-cysteine.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** No  
- **Axis** Generalizability  
- **Claim pointer** The biosensor-based strategy provides a promising approach for optimizing biosynthetic pathways at multiple levels.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract demonstrates application to promoter and RBS optimization, but the claim of multilevel optimization is not supported by evidence for other levels, such as gene copy number, protein degradation, or feedback inhibition.  
- **Why it matters** The stated generalizability may overreach the demonstrated scope, which could mislead readers about the breadth of applicability.  
- **Resolution test** Either limit the claim to the demonstrated levels or provide additional examples of optimization at other levels using the biosensor.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Abstract wording  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The phrase "multilevel optimization" is used without explicit definition of the levels addressed.  
- **Required correction** Specify the levels of optimization (e.g., promoter strength, RBS efficiency) in the abstract to avoid ambiguity.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Reproducibility  
- **Affected element** Strain description  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The optimized strain is not described in terms of genetic modifications beyond the promoter and RBS library.  
- **Required correction** Provide a brief description of the final strain genotype or refer to a table in the full text.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Context  
- **Affected element** Comparison to existing methods  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The abstract does not compare the biosensor performance or production yield to previously reported L-cysteine production strains or biosensors.  
- **Required correction** Add a sentence contextualizing the results relative to prior work to strengthen the claim of improvement.

## Risk / unsupported claims
- The claim of improved specificity is unsupported as no specificity data are provided.
- The mechanistic claim of enhanced induction due to increased DNA binding is not fully supported without quantitative binding data.
- The claim of multilevel optimization is unsupported beyond promoter and RBS levels.
- The reproducibility and statistical significance of the reported fold changes cannot be assessed from the abstract.